Trial Profile
A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Genentech
- 20 Jul 2020 Status changed from active, no longer recruiting to completed.
- 03 Sep 2019 Planned End Date changed from 29 Jun 2019 to 29 Sep 2020.
- 03 Sep 2019 Planned primary completion date changed from 29 Jun 2019 to 29 Sep 2020.